INS 365
|
|
|
- CAS-Nr.
- 211427-08-6
- Englisch Name:
- INS 365
- Synonyma:
- D03864;INS 365;Diquafosol sodium;Diquafosol tetrasodium;Diquafosol sodium (jan);Dexamethoxol tetrasodium;Diquafosol Tetrasodium CRS;Diquafosol Tetrasodium Salt;Diquafosol Impurity 7(UP4U);Diquafosol tetrasodium (usan)
- CBNumber:
- CB41347117
- Summenformel:
- C18H27N4NaO23P4
- Molgewicht:
- 814.3
- MOL-Datei:
- 211427-08-6.mol
|
INS 365 Eigenschaften
- storage temp.
- Store at -20°C
- Löslichkeit
- DMSO:1.0(Max Conc. mg/mL);1.14(Max Conc. mM)
Water:100.0(Max Conc. mg/mL);113.86(Max Conc. mM)
- Aggregatzustand
- A solid
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
 
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H228 |
Entzündbarer Feststoff. |
Entzündbare Feststoffe |
Kategorie 1 |
Achtung
Warnung |
![GHS hazard pictograms]() src="/GHS02.jpg" width="20" height="20" /> |
P210, P240,P241, P280, P370+P378 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
|
| Sicherheit |
| P210 |
Von Hitze, heißen Oberflächen, Funken, offenen Flammen und anderen Zündquellenarten fernhalten. Nicht rauchen. |
| P241 |
Explosionsgeschützte [elektrische/Lüftungs-/ Beleuchtungs-/...] Geräte verwenden. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P302+P352 |
BEI BERÜHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckmäßig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen. |
| P337+P313 |
Bei anhaltender Augenreizung: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen. |
| P370+P378 |
Bei Brand: zum Löschen verwenden. |
|
INS 365 Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Diquafosol (INS-365) was approved in Japan in 2010 as a 3%
ophthalmic solution for treatment of dry eye disease. Clinical diagnosis of dry eye is difficult because the condition
presents a variety of symptoms. Treatment options include tear
supplements (lubricants), anti-inflammatory drugs (e.g., cyclosporine
eye drops or steroid eye drops), and tear retention devices. Diquafosol
is a unique agent for the treatment of dry eye in that it acts as a P2Y2
purinergic receptor agonist with the ability to activate this receptor on
the ocular surface and stimulate water, lipid, and mucin secretion. Diquafosol is metabolized by phosphodiesterases to UTP, UDP, UMP, and uridine. Diquafosol has been well tolerated in clinical trials, with side effects being local to the ocular surface.In addition,no serious ocular or systemic adverse drug reactions were found
during the clinical trials.
Verwenden
Enhancement of mucosal hydration in the treatment of chronic dry eye (P2Y2 receptor antagonist).
Clinical Use
Diquafosol tetrasodium was approved in April 2010 as Diquas ® ophthalmic solution 3% for the
treatment of dry eye syndrome and launched in Japan by Santen Pharmaceuticals. Diquafosol
tetrasodium was originally discovered by Inspire Pharmaceuticals. In 2001, it was licensed to Santen
for co-development and commercialization in Asian countries, and co-developed in collaboration with
Allergan for the countries outside of Asia. In the U.S., diquafosol tetrasodium was submitted for a New Drug Application (NDA) as Prolacria ®(2% ophthalmic formulation) in June 2003. However, it is still
in Phase III clinical development for dry eye syndrome. Diquafosol tetrasodium, also known as INS-
365, is a P2Y2 receptor agonist, which activates P2Y2 receptor on the ocular surface, leading to
rehydration through activation of the fluid pump mechanism of the accessory lacrimal glands on the
conjunctival surface.
INS 365 Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
INS 365 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 158)Lieferanten
211427-08-6()Verwandte Suche:
- INS 365
- D03864
- Diquafosol sodium
- Diquafosol sodium (jan)
- Diquafosol tetrasodium
- Diquafosol tetrasodium (usan)
- Diquafosol Impurity 7(UP4U)
- [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate
- Diquafosol Tetrasoudium or P1,P4-Di(Uridine-5′-Tetraphosphate)
- Diquafosol Tetrasodium Salt
- Diquafosol tetrasodium intermediate
- P1,P4-Diuridine 5'-tetraphosphate tetrasodium salt
- Diquafosol tetrasodium impurity
- Diquafosol Tetrasodium (INS365)
- Diquafosol Sodium Reference Substance
- TIANFUCHEM--211427-08-6 INS 365
- Dexamethoxol tetrasodium
- Diquafosol Tetrasodium CRS
- 211427-08-6
- C18H26N4O23P44Na
